EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acquired and intrinsic resistance to vemurafenib in BRAF V600E ‐driven melanoma brain metastases

Ping Zhang, Laura Esmee Kuil iD, Levi Conrad Maria Buil, Stephan Freriks, Jos Hendrik Beijnen iD, Olaf van Tellingen iD, Mark Cornelis de Gooijer iD

FEBS Open Bio · 2024-01 · 14 (1) · 96-111

DOI: 10.1002/2211-5463.13730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 30.11.2023. Verfasst von Ping Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Melanoma, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting STOPhersentumoren.nl.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF V600 ‐mutated melanoma brain metastases (MBMs) are responsive to BRAF inhibitors, but responses are generally less durable than those of extracranial metastases. We tested the hypothesis that the drug efflux transporters P‐glycoprotein (P‐gp; ABCB1) and breast cancer resistance protein (BCRP; ABCG2) expressed at the blood–brain barrier (BBB) offer MBMs protection from therapy. We intracranially implanted A375 melanoma cells in wild‐type (WT) and Abcb1a/b;Abcg2 −/− mice, characterized the tumor BBB, analyzed drug levels in plasma and brain lesions after oral vemurafenib administration, and determined the efficacy against brain metastases and subcutaneous lesions. Although contrast‐enhanced MRI demonstrated that the integrity of the BBB is disrupted in A375 MBMs, vemurafenib achieved greater antitumor efficacy against MBMs in Abcb1a/b;Abcg2 −/− mice compared with WT mice. Concordantly, P‐gp and BCRP are expressed in MBM‐associated brain endothelium both in patients and in A375 xenografts and expression of these transporters limited vemurafenib penetration into A375 MBMs. Although initially responsive, A375 MBMs rapidly developed therapy resistance, even in Abcb1a/b;Abcg2 −/− mice, and this was unrelated to pharmacokinetic or target inhibition issues. Taken together, we demonstrate that both intrinsic and acquired resistance can play a role in MBMs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaBrain NeoplasmsHumansAnimalsMiceVemurafenibATP Binding Cassette Transporter, Subfamily G, Member 2Proto-Oncogene Proteins B-rafSulfonamidesIndolesATP-Binding Cassette TransportersNeoplasm Proteins

Stichwörter der Autor:innen

BRAFblood-brain barrierbrain metastasesmelanomaresistancevemurafenib

Substanzen

VemurafenibATP Binding Cassette Transporter, Subfamily G, Member 2Proto-Oncogene Proteins B-rafSulfonamidesIndolesATP-Binding Cassette TransportersNeoplasm ProteinsBRAF protein, human

Autor:innen und Institutionen

  • Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, China.
  • Shandong Provincial Key Laboratory of Brain Function Remodeling, Qilu Hospital, Shandong University, China.
  • Division of Psychosocial Sciences and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Mouse Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/MC Slotervaart Hospital, Amsterdam, The Netherlands.

ORCID-Profile: Laura Esmee Kuil, Jos Hendrik Beijnen, Olaf van Tellingen, Mark Cornelis de Gooijer

Förderung

  • Stichting STOPhersentumoren.nl

Zitieren

APA

Zhang, P., Kuil, L. E., Buil, L. C. M., Freriks, S., Beijnen, J. H., van Tellingen, O., & de Gooijer, M. C. (2024). Acquired and intrinsic resistance to vemurafenib in BRAF V600E ‐driven melanoma brain metastases. FEBS Open Bio, 14(1), 96-111. https://doi.org/10.1002/2211-5463.13730

Vancouver

Zhang P, Kuil LE, Buil LCM, Freriks S, Beijnen JH, van Tellingen O, et al. Acquired and intrinsic resistance to vemurafenib in BRAF V600E ‐driven melanoma brain metastases. FEBS Open Bio. 2024;14(1):96-111. doi:10.1002/2211-5463.13730

BibTeX
@article{Zhang2024,
  author = {Zhang, Ping and Kuil, Laura Esmee and Buil, Levi Conrad Maria and Freriks, Stephan and Beijnen, Jos Hendrik and van Tellingen, Olaf and de Gooijer, Mark Cornelis},
  title = {Acquired and intrinsic resistance to vemurafenib in BRAF V600E ‐driven melanoma brain metastases},
  journal = {FEBS Open Bio},
  year = {2024},
  volume = {14},
  number = {1},
  pages = {96--111},
  doi = {10.1002/2211-5463.13730}
}
Kostenlos starten →